62results about How to "Prolong biological half-life" patented technology

The invention discloses a long-chain recombination human bone pattern generating protein-2 and preparing method and application, which is characterized by the following: utilizing gene project technique to grow the protein in the expressing system of escherichia coli and bacillus subtilis; adopting human bone sarcoma cell mRNA to do reverse transcription to obtain the cDNA as form; augmenting nucleotide sequence of entire 114 amino acids naturally from carboxyl end; adding a segment of nucleotide in front of the first codon of primer 5' end; increasing a segment of polypeptide at N end corresponding to amino acid sequence; obtaining long-chain rhBMP-2 gene with molecular weight at 30KD and purity over 95%.

The invention relates to long-acting glucagon-like peptide 1 (GLP-1) analogues and a synthesis method thereof. GLP-1 analogues with longer pharmacological action time are obtained through adding a modified 37th amino acid to natural GLP-1, the synthesis of target polypeptides is quickly realized through a microwave-promoted solid-phase synthesis method, and crude products are purified and freeze-dried to obtain the GLP-1 analogues.

The invention provides polyethylene glycol modified L-Asparaginasum shown as formula (1) and a modification method thereof. The method uses the modification reaction property of polyethylene glycol molecules to modify the L-Asparaginasum under the condition of proper pH value of a reaction system. The polyethylene glycol modified L-Asparaginasum is characterized in that two polyethylene glycol molecules are covalently bound in a reaction product; and the substance has lower glomerular filtration rate and lower immunogenicity compared with a single polyethylene glycol molecule modifier so as to provide better antitumor effect.

The invention relates to glucagon-like peptide 1 (GLP-1) analogues with a long-acting effect and a synthesis method thereof. GLP-1 analogues with longer pharmacological action time are obtained through replacing/modifying 17th, 26th, 34th and 37th amino acids of natural GLP-1, the synthesis of target polypeptides is quickly realized through a microwave-promoted solid-phase synthesis method, and crude products are purified and freeze-dried to obtain the GLP-1 analogues.

This invention provides new compounds and uses thereof in treating a variety of diseases or conditions in a subject, including,inter alia, prostate cancer, muscle wasting diseases and/or disorders or a bone-related diseases and/or disorders.

The invention discloses total bufadienolide solid lipid nanometer particle freeze-dried injection and a preparation method thereof and belongs to field of the solid lipid nanometer particle freeze-dried injection and the preparation method thereof. The invention firstly discloses a total bufadienolide solid lipid nanometer particle which comprises the following components: total bufadienolide, solid lipid, a lipid-soluble emulsifying agent, a water-soluble emulsifying agent and water for injection. The total bufadienolide solid lipid nanometer particle is added with a freeze-drying protective agent and then freeze-dried to obtain the total bufadienolide solid lipid nanometer particle freeze-dried injection. After the total bufadienolide solid lipid nanometer particle freeze-dried injection disclosed by the invention is redissolved, the measured particle size of the total bufadienolide solid lipid nanometer particle is 190nm to 250nm, the polydispersity index is 0.18 to 0.3, the encapsulation efficiency is 30% to 80%, the tumor cell targeting property of the total bufadienolide can be effectively improved, and toxic and side effects are alleviated.

This invention provides a novel class of androgen receptor targeting agents (ARTA). The agents define a new subclass of compounds which are tissue-selective androgen receptor modulators (SARM), which are useful for oral testosterone replacement therapy, male contraception, maintaining sexual desire in women, treating prostate cancer and imaging prostate cancer. These agents have an unexpected in-vivo activity for an androgenic and anabolic activity of a nonsteroidal ligand for the androgen receptor. These agents may be active alone or in combination with progestins or estrogens. The invention further provides a novel class of nonsteroidal agonist compounds and methods of binding an androgen receptor, modulating spermatogenesis, treating and imaging prostate cancer, and providing hormonal therapy for androgen-dependent conditions.

The invention relates to novel long-acting glucagon-like peptide 1 (GLP-1) analogues and a synthesis method thereof. GLP-1 analogues with longer pharmacological action time are obtained through replacing/modifying 17th, 26th, 34th and 37th amino acids of natural GLP-1, the synthesis of target polypeptides is quickly realized through a microwave-promoted solid-phase synthesis method, and crude products are purified and freeze-dried to the GLP-1 analogues.

The invention discloses an IgG-like long-acting immunological fusion protein and applications thereof. The IgG-like long-acting immunological fusion protein comprises an effector molecule and an IgG antibody constant region, wherein the effector molecule is linked to the IgG antibody constant region through a linker peptide, the effector molecule is a protein capable of exerting physiological functions in vivo, and the IgG antibody constant region is a structure obtained by removing two heavy chain variable regions and two light chain variable regions from an IgG antibody. According to the present invention, the IgG-like immunological fusion protein can effectively prolong the biological half-life of the protein drug (effector molecule) under the premise of the ensuring of the high affinity to the targeting molecule and the good in vivo activity, is far better than the similar Fc immunological fusion protein, and can be used for the treatment of diabetes, tumors, autoimmune diseases, endocrine and various diseases.

The invention relates to stable aqueous solution of a recombinant human serum albumin-interferon alpha fusion protein and belongs to the technical field of biological preparations. The aqueous solution of the recombinant human serum albumin-interferon alpha fusion protein is prepared by dissolving the recombinant human serum albumin-interferon alpha fusion protein and pharmaceutically acceptable stable auxiliary material in pharmaceutically acceptable buffer solution, and is characterized in that the pharmaceutically acceptable stable auxiliary material is arginine at a concentration of 5 to 30 g/L. The aqueous solution of therecombinant human serum albumin-interferon alpha fusion protein can prevent the aggregation, degradation, oxidation, denaturation and the like of the recombinant fusion protein effectively so as to retain bioactivity and is suitable to be used in clinic.

A method for producing an iodine radioisotopes fraction, comprising the steps of dissolving enriched uranium targets forming a slurry, filtering the slurry, absorbing salts of iodine radioisotopes onan aluminium resin doped with silver and recovering the iodine radioisotopes fraction. The recovery of the iodine radioisotopes fraction, in particular of I-131, comprises washing the aluminium resindoped in silver using a solution of NaOH and eluting of iodine radioisotopes by a solution of thiourea, and collecting an eluate containing the iodine radioisotopes in a theourea solution.

The invention relates to the field of medicinal preparations, and in particular relates to a heparin-modified adriamycin liposome (Hep-DOX-Lip) preparation. The preparation is characterized by consisting of 1 part of adriamycin, 1-4 parts of heparin, 5-30 parts of soybean lecithin, 0.5-4 parts of cholesterol and 0.5 part of a cationic material. The invention further discloses a preparation method of the heparin-modified adriamycin liposome preparation. The heparin-modified adriamycin liposome preparation has an effect similar to pegylation, and can remarkably enhance the stability of an adriamycin liposome, prolong the in-vivo half-life period of a medicament, and enhance the bioavailability of the medicament. Meanwhile, the heparin-modified adriamycin liposome preparation can remarkably lower the toxic and side effects of chemotherapeutic drugs and enhance the compliance of patients.

Disclosed are a preparation method for hepatic receptor imaging agent 99mTc-galactosyl-human serum albumin fusion interferon and the application of the albumin fusion interferon, belonging to the nuclear medicine technical field. The invention adopts a stannous reduction method for the radioactive technetium tagging of the hepatic receptor imaging agent 99mTc-galactosyl-human serum albumin fusion interferon GHSA-IFN; upon polyamide-66 thin layer chromatography analysis, the radiochemical purity of the prepared 99mTc-GHSA-IFN is more than 90% and can be stabilized for more than 6 hours at room temperature, in line with the requirements of scientific research and clinical use. The distribution in mice and the imaging results of rats show that the 99mTc-GHSA-IFN can be incepted by liver in a specific way, and the liver imaging is very clear within 10-30 minutes which is the best time for liver imaging. Therefore, the 99mTc-GHSA-IFN is a good new liver receptor function SPECT imaging agent and can be used to evaluate the liver receptor functions, diagnose liver diseases and evaluate the liver disease treatment drug efficacy; at the same time, the 99mTc-GHSA-IFN is also used to prepare liver targeted therapy drugs and the treatment drugs for viral hepatitis.

The invention discloses a preparation method and application of a triptolide-carboxylation chitosan coupling drug. The preparation method comprises the following steps: (1) synthesis of intermediate carboxylation triptolide (TP-L); and (2) synthesis of the triptolide-carboxylation chitosan coupling drug (TP-L-CChit). The triptolide-carboxylation chitosan coupling drug (TP-L-CChit) prepared by themethod, as a pro-drug, has application for preparing drugs for treating rheumatoid arthritis, tumors and Alzheimer's disease; the drug is simple in method, easy for production preparation, high in yield and rich and easily obtained in raw materials, the product is high in water solubility, long in biological half life period, high in availability, free of toxic or side effect and good in curativeeffect and is innovation for preparing drugs for treating rheumatoid arthritis, tumors and Alzheimer's disease, and the economic and social benefits are obvious.

The invention discloses a compound medicinal composition for reducing blood pressure and a compound tablet for reducing blood pressure. The compound medicinal composition for reducing blood pressure comprises levamlodipine or pharmaceutically acceptable salt thereof and indapamide, wherein the weight ratio of indapamide to levamlodipine is 1:(1.5-12). The novel compound preparation for reducing blood pressure improves the effect of reducing blood pressure by using synergism among medicines, has a stable effect of reducing blood pressure and excellent cost performance, reduces a side effect, and can be widely popularized and applied to crowds. The compound tablet for reducing blood pressure has high stability and can effectively prolong a validity period.

The invention provides a process for preparing nanometer particle of adriacin-PACA-PBCA, which comprises, reacting HCl solution with doxorubicin hydrochloride powder, stirring to dissolve, charging Dextran70 and charging alpha-butylcyanoacrylate, stirring and adjusting pH to be 7, passing through 0.45um filtration film and drying.

The invention discloses a total bufogenin nano cubic liquid crystal and a preparation method thereof. The total bufogenin nano cubic liquid crystal is composed of a lipid material, an emulsifying agent and purified water. The total bufogenin nano cubic liquid crystal provided by the invention is characterized in that amphipathic lipid with certain concentration spontaneously forms double layers of the lipid in water, and the double layers are assembled into a cubic liquid crystal form with thermodynamic stability. The total bufogenin nano cubic liquid crystal disclosed by the invention increases the medicine solubility, realizes the oral administration of lipid-soluble medicine total bufogenin, adjusts and controls the medicine release, improves the medicine bioavailability, effectively improves the tumor cell targeting property of total bufogenin, and reduces toxic or side effects.

The invention belongs to the technical field of molecular biology and in particular relates to a tumor blood vessel and M1 type macrophage targeting peptide and application thereof. Aiming at the problem that a small molecular targeting peptide for preparing a medicine for diagnosing or treating tumors is lacked, the invention provides the tumor blood vessel and M1 type macrophage targeting peptide TCP-2 and a carrier thereof. The small molecular targeting peptide has an amino acid sequence shown as SEQ ID NO: 1, can be used for specifically targeting tumor blood vessels and M1 type macrophages and can be used for preparing the targeting medicine for diagnosing or treating the tumors; especially, the mall molecular targeting peptide is used for treating digestive tract tumors and providesa new choice for targeting therapy of the tumors.

The present invention relates to a sort of making method for the Alpha-interferon modified by the covalent bond of the activating polyethyleneglycol. By changing the acid-base scale of the reaction system it can achieve the purpose that modifies the histidine or lysine in the surface of the Alpha-interferon protein. During the course of reaction there is no need to separate the raw material of Alpha-interferon 1 b from the intermediate product, the novel compound which is modified by the polyethyleneglycol of Alpha-interferon 1 b can retain the biological activity of the former Alpha-interferon 1 b, but in pharmacology, immunogen character, medicine substituting character, medicine effect and the like aspects it gains an advantage over the former protein.

The invention relates to a novel peptide conjugate of African clawed frog GLP-1 (glucagon like peptide-1), as well as a synthesis method and application thereof. A spiral promoting sequence is introduced to a terminal C of the African clawed frog GLP-1, and meanwhile, PEG (polyethylene glycol)-based modification is performed to obtain an analogue, with reserved hypoglycemic activity and longer pharmacological action time, of the African clawed frog GLP-1. The analogue of the African clawed frog GLP-1 has the advantages of high synthesis yield and low cost, the half-life of the analogue is remarkably prolonged, and the bioactivity is remarkably improved.

The invention relates to a long-acting African clawed frog glucagon-like peptide-1 (GLP-1) analogue as well as a synthesis method and application thereof. An African clawed frog glucagon-like peptide-1 is subjected to PEG (Polyethylene Glycol) modification to obtain the African clawed frog GLP-1 analogue which can keep blood glucose lowering activity and has longer pharmacological action time. The African clawed frog GLP-1 analogue provided by the invention is high in synthesis yield and low in cost; and the half-life period of the analogue is remarkably prolonged and the biological activity is remarkably improved.

The invention relates to a magnesium valproate sustained release tablet and a preparation process thereof. The magnesium valproate sustained release tablet is prepared from the following two parts: A,a tablet core prepared from the following substances: 29 to 54 percent of magnesium valproate, 17 to 21 percent of hydroxypropyl methylcellulose, 2 to 9 percent of ethylcellulose, 22 to 30 percent ofethyl alcohol, 0.8 to 4 percent of magnesium stearate, and 3 to 7 percent of talcum powder; B, a sustained release tablet coating formula prepared from the following substances: 0.7 to 2 percent of ethylcellulose, 0.7 to 1.3 percent of glycerinum, 1.3 to 4 percent of hydroxypropyl methylcellulose, and 0.3 to 1.3 percent of talcum powder. The preparation process comprises: A, a preparation processof the tablet core, comprising the steps of weighing raw materials according to tablet core formula amounts uniformly mixing, adding an appropriate amount of the ethyl alcohol, preparing a soft material, sieving and pelletizing, then baking and drying at the temperature of 55 DEG C to 65 DEG C, adding the magnesium stearate and the talcum powder, uniformly mixing, measuring the content, and pressing to form an oval tablet; B, a preparation process of the coating comprising the steps of weighing ingredients according to sustained release tablet coating formula amounts, dissolving through an appropriate amount of 50 to 100 percent ethyl alcohol, and then spraying a coating on the tablet core.

The invention discloses a preparation method and application of an engineering bionic exosome for delivering specific protein. The preparation method comprises the following steps: S1, packaging viruses by using engineering cells to prepare specific lentiviral particles; S2, infecting target cells by using the obtained lentivirus, and adding a resistant drug for screening, so as to prepare a stable cell line for expressing a specific gene with high purity; and S3, culturing the obtained stable cell line, extracting cell membranes of the stable cell line, preparing the stable cell line into membrane nano-vesicles, and finally performing centrifugal purification to obtain the engineering bionic exosome. The invention provides a synthetic method for preparing a large number of specific protein drug delivery systems, the method can effectively enhance the stability of protein biomacromolecule drugs in vivo, prolong the drug effect duration and realize effective delivery of the drugs, a newthought is provided for the administration route of the protein biomacromolecule drugs, the engineering bionic exosome can be used for immunotherapy for treating tumors, is good in safety and strongin action effect, and has very high application value and clinical transformation prospect.

The invention discloses a method for preparing hydrophobic drug-carrying core-shell structure micro/nanoparticles through electrostatic spraying, and relates to the field of pharmaceutics. The method comprises the following steps: jointly dissolving a hydrophobic drug and a lipid solubility high polymer material in an organic solvent, emulsifying and dissolving in an aqueous solution containing a water-soluble polymer material; and putting the obtained oil-in-water emulsion in a trace propeller, carrying out electrostatic spraying under the effect of a high-voltage electrostatic field, and thus finally obtaining the hydrophobic drug-carrying core-shell structure micro/nanoparticles. The preparation method is simple to operate, low in cost, environment-friendly and suitable for industrial production. The prepared hydrophobic drug-carrying core-shell structure micro/nanoparticles are controllable in particle sizes, have targeting property on tissues and organs and are beneficial to prolonging of action time of the drug.

The invention relates to application of a covalent organic nanosheet material to preparation of a medicine for preventing and/or treating radiation damage caused by radionuclide. The covalent organicnanosheet material comprises a plurality of amidoxime groups. The invention discloses the novel application of the covalent organic nanosheet material. The radionuclide is chelated and coordinated byutilizing the synergistic effect of multiple pieces of amidoxime, the covalent organic nanosheet material has very high selectivity on radionuclide, and the bottlenecks of fast metabolism, strong toxicity and poor excretion promoting effect of a conventional small molecular ligand are broken through.